Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Subfoveal Choroidal Neovascularization Clear all
Completed Phase 3 Interventional

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03834753
View directory record Official record
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
50
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jul 22, 2026, 5:48 PM EDT
Not listed Phase 3 Interventional

A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration

NCT00454389
View directory record Official record
Conditions
Macular Degeneration
Interventions
Epi-Rad90™ Ophthalmic System, ranibizumab
Device · Drug
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Proton Radiation Therapy for Macular Degeneration

NCT01833325
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Proton radiation
Radiation
Lead sponsor
University of Florida
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 3 Interventional

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

NCT00058994
View directory record Official record
Conditions
Macular Degeneration, Maculopathy, Age-Related
Interventions
anecortave acetate
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

NCT00242580
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

NCT00436553
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

NCT00363714
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
AGN211745
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2008 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)

NCT01175395
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
IBI-20089/Lucentis
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration

NCT00259753
View directory record Official record
Conditions
Macular Degeneration
Interventions
Bevasiranib
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Artesia, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 3 Interventional

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

NCT00090623
View directory record Official record
Conditions
Macular Degeneration
Interventions
rhuFab V2 (ranibizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jul 22, 2026, 5:48 PM EDT
Not listed Phase 1Phase 2 Interventional

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

NCT02599064
View directory record Official record
Conditions
Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
Interventions
RXI-109
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Jul 22, 2026, 5:48 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

NCT01940900
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
E10030, ranibizumab, E10030 sham intravitreal injection
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
49
States / cities
Tucson, Arizona • Fresno, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

NCT00138632
View directory record Official record
Conditions
Wet Age-Related Macular Degeneration
Interventions
PTK787, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
Beverly Hills, California • Denver, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2008 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

NCT00426998
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Verteporfin, Bevacizumab
Drug
Lead sponsor
Retinal Consultants Medical Group
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

NCT00088192
View directory record Official record
Conditions
Macular Degeneration
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
20
States / cities
Los Angeles, California • Bridgeport, Connecticut • Hamden, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2005 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

NCT04005352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 22, 2026, 5:48 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

NCT00090532
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
AG-013,958
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Mesa, Arizona • Oro Valley, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Jul 22, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

NCT01122511
View directory record Official record
Conditions
Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
Interventions
700 ug dexamethasone, ranibizumab, sham
Drug · Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2012 · Synced Jul 22, 2026, 5:48 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

NCT02228304
View directory record Official record
Conditions
Macular Degeneration
Interventions
NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
Drug
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Jul 22, 2026, 5:48 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

NCT01940887
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
E10030, bevacizumab or aflibercept, E10030 sham injection
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
100
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

NCT04597632
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 22, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

NCT00089830
View directory record Official record
Conditions
Macular Degeneration
Interventions
MSI-1256F (Squalamine Lactate)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Plymouth Meeting, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced Jul 22, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

NCT00749021
View directory record Official record
Conditions
Retinal Pigment Epithelial Detachment
Interventions
Ranibizumab
Drug
Lead sponsor
Clement K. Chan
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Palm Desert, California • Rapid City, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Jul 22, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

NCT02387957
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Fovista®, bevacizumab, ranibizumab, aflibercept
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Jul 22, 2026, 5:48 PM EDT